Immunocore Email Format

Biotechnology Research
201-500 employees
Abingdon, England, UK

Immunocore is a biotechnology company developing first-in-class T cell receptor therapies to address unmet patient needs in oncology, infectious diseases, and autoimmune conditions.

Find contacts at Immunocore

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@immunocore.com

Company Overview

Industry
Biotechnology Research
Founded
2008
Headquarters
Abingdon, England, UK
Revenue
$250M-$500M
FUNDING Stage
Private
Key Executives
Bahija Jallal (Chief Executive Officer), Travis Coy (EVP, Chief Financial Officer and Head of Corporate Development), Kripa Ram (EVP, Chief Operating Officer)

Tech Stack

Microsoft Azure

Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Immunocore?

Immunocore uses the first.last format, so Jane Smith would be jane.smith@immunocore.com.

What is Immunocore's approved therapy and what cancer does it treat?

Immunocore's approved therapy is KIMMTRAK (tebentafusp), indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. It is approved in the US, EU, Canada, Australia, and the UK, and entered its fifth year post-approval in 2026.

How does Immunocore's ImmTAX platform work?

Immunocore's ImmTAX platform generates bispecific T cell receptor biologics, called ImmTAC molecules, that redirect and activate T cells to recognize and destroy cancer cells or infected cells. The platform is designed to be modular and off-the-shelf, covering oncology, infectious diseases, and autoimmune diseases.

Which therapeutic areas does Immunocore's pipeline cover beyond oncology?

Beyond oncology, Immunocore has pipeline programs in infectious diseases and autoimmune diseases, including a Phase 1/2 HIV candidate and early-stage programs targeting type 1 diabetes and atopic dermatitis, with clinical milestones planned across all three areas in 2026.

Where is Immunocore headquartered, and who leads the company?

Immunocore is headquartered in Abingdon, England, UK. Bahija Jallal serves as Chief Executive Officer, with Travis Coy as EVP and Chief Financial Officer and Kripa Ram as EVP and Chief Operating Officer. Tools like Clay can help you find and verify the right contact at Immunocore for outreach.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles